These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
149 related articles for article (PubMed ID: 15911475)
21. Early stopping rules in oncology: considerations for clinicians. Mukherjee SD; Goffin JR; Taylor V; Anderson KK; Pond GR Eur J Cancer; 2011 Nov; 47(16):2381-6. PubMed ID: 21684153 [TBL] [Abstract][Full Text] [Related]
22. Regarding paper "Five interval estimators for proportion ratio under a stratified randomized clinical trial with noncompliance" by Lui K. J. and Chang K. C. Vach W Biom J; 2007 Aug; 49(4):627-9; author reply 630-1. PubMed ID: 17722194 [No Abstract] [Full Text] [Related]
23. Comments on 'maintaining confidentiality of interim data to enhance trial integrity and credibility' by TR Fleming et al. Korn EL; Hunsberger S; Freidlin B; Smith MA; Abrams JS Clin Trials; 2008; 5(4):364-5; author reply 365-6. PubMed ID: 18697851 [No Abstract] [Full Text] [Related]
24. Stopping rules, interim analyses and data monitoring committees. Ashby D; Machin D Br J Cancer; 1993 Dec; 68(6):1047-50. PubMed ID: 8260354 [No Abstract] [Full Text] [Related]
25. IVF with preimplantation genetic screening, a promising new treatment with unexpectedly negative health outcomes: the Hippocratic role of Data Monitoring Committees. Ankum WM; Reitsma JB; Offringa M; Hum Reprod; 2008 Jan; 23(1):1-3. PubMed ID: 18029343 [TBL] [Abstract][Full Text] [Related]
29. How to deal with multiple treatment or dose groups in randomized clinical trials? Hothorn LA Fundam Clin Pharmacol; 2007 Apr; 21(2):137-54. PubMed ID: 17391286 [TBL] [Abstract][Full Text] [Related]
30. Design of randomized controlled trials. Stanley K Circulation; 2007 Mar; 115(9):1164-9. PubMed ID: 17339574 [No Abstract] [Full Text] [Related]
31. Modelling clustered survival data from multicentre clinical trials. Glidden DV; Vittinghoff E Stat Med; 2004 Feb; 23(3):369-88. PubMed ID: 14748034 [TBL] [Abstract][Full Text] [Related]
34. [Monitoring the safety of participants in randomised clinical trials: basis and methods]. Tijssen JG Ned Tijdschr Geneeskd; 2008 Mar; 152(12):674-8. PubMed ID: 18438062 [TBL] [Abstract][Full Text] [Related]
35. Estimating treatment efficacy over time: a logistic regression model for binary longitudinal outcomes. Choi L; Dominici F; Zeger SL; Ouyang P Stat Med; 2005 Sep; 24(18):2789-805. PubMed ID: 16134133 [TBL] [Abstract][Full Text] [Related]
36. Misspecified regression model for the subdistribution hazard of a competing risk. Latouche A; Boisson V; Chevret S; Porcher R Stat Med; 2007 Feb; 26(5):965-74. PubMed ID: 16755533 [TBL] [Abstract][Full Text] [Related]
37. What's time got to do with it? Inattention to duration in interpretation of survival graphs. Zikmund-Fisher BJ; Fagerlin A; Ubel PA Risk Anal; 2005 Jun; 25(3):589-95. PubMed ID: 16022692 [TBL] [Abstract][Full Text] [Related]
39. Dynamic comparison of Kaplan-Meier proportions: monitoring a randomized clinical trial with a long-term binary endpoint. Brittain E; Follmann D; Yang S Biometrics; 2008 Mar; 64(1):189-97. PubMed ID: 17680830 [TBL] [Abstract][Full Text] [Related]
40. Comparing outcomes on peritoneal and hemodialysis: a case study in the interpretation of observational studies. Davies SJ Saudi J Kidney Dis Transpl; 2007 Mar; 18(1):24-30. PubMed ID: 17237887 [No Abstract] [Full Text] [Related] [Previous] [Next] [New Search]